TY - JOUR
T1 - Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period
T2 - Findings from the PSERENADE Project
AU - PSERENADE Team
AU - Quesada, Maria Garcia
AU - Yang, Yangyupei
AU - Bennett, Julia C.
AU - Hayford, Kyla
AU - Zeger, Scott L.
AU - Feikin, Daniel R.
AU - Peterson, Meagan E.
AU - Cohen, Adam L.
AU - Almeida, Samanta C.G.
AU - Ampofo, Krow
AU - Ang, Michelle
AU - Bar-Zeev, Naor
AU - Bruce, Michael G.
AU - Camilli, Romina
AU - Chacón, Grettel Chanto
AU - Ciruela, Pilar
AU - Cohen, Cheryl
AU - Corcoran, Mary
AU - Dagan, Ron
AU - De Wals, Philippe
AU - Desmet, Stefanie
AU - Diawara, Idrissa
AU - Gierke, Ryan
AU - Guevara, Marcela
AU - Hammitt, Laura L.
AU - Hilty, Markus
AU - Ho, Pak Leung
AU - Jayasinghe, Sanjay
AU - Kleynhans, Jackie
AU - Kristinsson, Karl G.
AU - Ladhani, Shamez N.
AU - McGeer, Allison
AU - Mwenda, Jason M.
AU - Pekka Nuorti, J.
AU - Oishi, Kazunori
AU - Ricketson, Leah J.
AU - Sanz, Juan Carlos
AU - Savrasova, Larisa
AU - Setchanova, Lena Petrova
AU - Smith, Andrew
AU - Valentiner-Branth, Palle
AU - Valenzuela, Maria Teresa
AU - van der Linden, Mark
AU - van Sorge, Nina M.
AU - Varon, Emmanuelle
AU - Winje, Brita A.
AU - Yildirim, Inci
AU - Zintgraff, Jonathan
AU - Knoll, Maria Deloria
AU - Zahin Amin-Chowdhury, Amin-Chowdhury
N1 - Publisher Copyright:
© 2021 by the authors.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.
AB - Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5-7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases <5 years of age and 15% among ≥5 years; the top serotypes were 19A, 6C, and 3, together causing 42% of cases <5 years and 37% ≥5 years. In PCV13-using sites (N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.
KW - Global
KW - Meta-analysis
KW - PCV impact
KW - Pneumococcal meningitis
KW - Serotype distribution
UR - http://www.scopus.com/inward/record.url?scp=85103604834&partnerID=8YFLogxK
U2 - 10.3390/microorganisms9040738
DO - 10.3390/microorganisms9040738
M3 - Article
C2 - 33916227
AN - SCOPUS:85103604834
SN - 2076-2607
VL - 9
JO - Microorganisms
JF - Microorganisms
IS - 4
M1 - 738
ER -